Back to mobile site

Charles River Laboratories (CRL) Tops Q4 EPS by 10c, Guides FY17 EPS In-Line

February 14, 2017 6:33 AM EST

Charles River Laboratories (NYSE: CRL) reported Q4 EPS of $1.21, $0.10 better than the analyst estimate of $1.11. Revenue for the quarter came in at $466.8 million versus the consensus estimate of $441.64 million.

GUIDANCE:

Charles River Laboratories sees FY2017 EPS of $5.00-$5.10, versus the consensus of $5.05.

  • Revenue growth, reported
  • 7.5% - 9.0%

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings